EFFICACY AND SAFETY OF RISANKIZUMAB: RESULTS FROM TWO DOUBLE-BLIND, PLACEBO- AND USTEKINUMAB-CONTROLLED, PHASE 3 TRIALS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

被引：0

作者：

Gordon, Kenneth B. ^{[1
]}

Strober, Bruce ^{[2
,3
]}

Lebwohl, Mark ^{[4
]}

Augustin, Matthias ^{[5
]}

Blauvelt, Andrew ^{[6
]}

Poulin, Yves ^{[7
]}

Papp, Kim A. ^{[8
,9
]}

Sofen, Howard ^{[10
]}

Puig, Lluis ^{[11
]}

Foley, Peter ^{[12
,13
,14
]}

Ohtsuki, Mamitaro ^{[15
]}

Flack, Mary ^{[16
]}

Geng, Ziqian ^{[17
]}

Gu, Yihua ^{[17
]}

Valdes, Joaquin M. ^{[17
]}

Thompson, Elizabeth H. Z. ^{[18
]}

Bachelez, Herve ^{[19
]}

机构：

[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[2] Univ Connecticut, Ctr Hlth, Farmington, CT USA

[3] Prob Med Res, Farmington, CT USA

[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[5] Univ Med Ctr Hamburg Eppendorf UKE, Hamburg, Germany

[6] Oregon Med Res Ctr, Portland, OR USA

[7] Ctr Dermatol Quebec Metropolitain, Quebec City, PQ, Canada

[8] K Papp Clin Res, Waterloo, ON, Canada

[9] Prob Med Res, Waterloo, ON, Canada

[10] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA

[11] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain

[12] Univ Melbourne, Parkville, Vic, Australia

[13] Skin & Canc Fdn Inc, Carlton, Vic, Australia

[14] Prob Med Res, Carlton, Vic, Australia

[15] Jichi Med Univ, Shimotsuke, Japan

[16] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA

[17] AbbVie Inc, N Chicago, IL USA

[18] AbbVie Inc, Redwood City, CA USA

[19] Univ Paris Diderot, Sorbonne Paris Cite, St Louis Hosp, Paris, France

来源：

ACTA DERMATO-VENEREOLOGICA | 2018年 / 98卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P062

引用

页码：28 / 29

页数：2

共 50 条

[41] Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study
Fiorillo, Loretta
Becker, Emily
de Lucas, Raul
Belloni-Fortina, Anna
Maes, Peter
Oberoi, Rajneet K.
Paris, Maria
Zhang, Wendy
Zhang, Zuoshun
Arkin, Lisa
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB122 - AB122
[42] Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study
Papp, Kim
Warren, Richard B.
Green, Lawrence
Reich, Kristian
Langley, Richard G.
Paul, Carle
Asahina, Akihiko
Johnson, Lynne
Arora, Vipin
Osuntokun, Olawale
Lebwohl, Mark
LANCET RHEUMATOLOGY, 2023, 5 (09): : E542 - E552
[43] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Tyring, Stephen K. K.
Rich, Phoebe
Tada, Yayoi
Beeck, Stefan
Messina, Izabella
Liu, Jie
Huang, Xiaohong
Shumack, Stephen
DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
[44] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Stephen K. Tyring
Phoebe Rich
Yayoi Tada
Stefan Beeck
Izabella Messina
Jie Liu
Xiaohong Huang
Stephen Shumack
Dermatology and Therapy, 2023, 13 : 595 - 608
[45] Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study
Bissonnette, R.
Haydey, R.
Rosoph, L. A.
Lynde, C. W.
Bukhalo, M.
Fowler, J. F.
Delorme, I.
Gagne-Henley, A.
Gooderham, M.
Poulin, Y.
Barber, K.
Jenkin, P.
Landells, I.
Pariser, D. M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (03) : 403 - 410
[46] Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
Gold, Linda Stein
Papp, Kim
Pariser, David
Green, Lawrence
Bhatia, Neal
Sofen, Howard
Albrecht, Lorne
Gooderham, Melinda
Chen, Mindy
Paris, Maria
Wang, Yao
Duffin, Kristina Callis
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (01) : 77 - 85
[47] Efficacy and safety of ixekizumab in a phaseIII, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)
Paller, A. S.
Seyger, M. M. B.
Alejandro Magarinos, G.
Bagel, J.
Pinter, A.
Cather, J.
Keller, S.
Rodriguez Capriles, C.
Gontijo Lima, R.
Gallo, G.
Little, C. A.
Edson-Heredia, E.
Li, L.
Xu, W.
Papp, K.
BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) : 231 - 241
[48] Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study
Seo, Seong Jun
Shin, Bong Seok
Lee, Joo-Heung
Jeong, Haeyoun
JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 807 - 817
[49] Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials
Gold, Linda Stein
Lebwohl, Mark G.
Sugarman, Jeffrey L.
Pariser, David M.
Lin, Tina
Martin, Gina
Pillai, Radhakrishnan
Israel, Robert
Ramakrishna, Tage
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) : 287 - 293
[50] Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
Ohtsuki, Mamitaro
Fujita, Hideki
Watanabe, Mitsunori
Suzaki, Keiko
Flack, Mary
Huang, Xin
Kitamura, Susumu
Valdes, Joaquin
Igarashi, Atsuyuki
JOURNAL OF DERMATOLOGY, 2019, 46 (08): : 686 - 694

← 1 2 3 4 5 →